Etanercept
- TRADE NAMES: Enbrel (Amgen); Erelzi (Sandoz)
- INDICATIONS: Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 years or older, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Antipsoriatic agent, Biologic, Biologic disease-modifying antirheumatic drug (bDMARD), Cytokine inhibitor, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 4–13 days
Abatacept, Anakinra, Cyclophosphamide, Live vaccines
PREGNANCY CATEGORY: B
TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
Contra-indicated in patients with sepsis.
TNF inhibitors are contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of etanercept in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/14/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric